دورية أكاديمية

Distinct Mechanisms of β-Arrestin-Biased Agonist and Blocker of AT1R in Preventing Aortic Aneurysm and Associated Mortality.

التفاصيل البيبلوغرافية
العنوان: Distinct Mechanisms of β-Arrestin-Biased Agonist and Blocker of AT1R in Preventing Aortic Aneurysm and Associated Mortality.
المؤلفون: Jara, Zaira Palomino, Harford, Terri J., Singh, Khuraijam Dhanachandra, Desnoyer, Russell, Kumar, Avinash, Srinivasan, Dasarathy, Karnik, Sadashiva S., Harford, Terri
المصدر: Hypertension (0194911X); Feb223, Vol. 80 Issue 2, p385-402, 18p
مستخلص: Background: Aortic aneurysm (AA) is a "silent killer" human disease with no effective treatment. Although the therapeutic potential of various pharmacological agents have been evaluated, there are no reports of β-arrestin-biased AT1R agonist (TRV027) used to prevent the progression of AA.Methods: We tested the hypothesis that TRV027 infusion in AngII-induced mouse model of AA prevents AA. High-fat-diet-fed ApoE-null mice were infused with AngII to induce AA and co-infused with TRV027 and a clinically used AT1R blocker Olmesartan to prevent AA. Aortas explanted from different ligand infusion groups were compared with assess different grades of AA or lack of AA.Results: AngII produced AA in ≈67% male mice with significant mortality associated with AA rupture. We observed ≈13% mortality due to aortic arch dissection without aneurysm in male mice. AngII-induced AA and mortality was prevented by co-infusion of TRV027 or Olmesartan, but through different mechanisms. In TRV027 co-infused mice aortic wall thickness, elastin content, new DNA, and protein synthesis were higher than untreated and Olmesartan co-infused mice. Co-infusion with both TRV027 and Olmesartan prevented endoplasmic reticulum stress, fibrosis, and vasomotor hyper responsiveness.Conclusions: TRV027-engaged AT1R prevented AA and associated mortality by distinct molecular mechanisms compared with the AT1R blocker, Olmesartan. Developing novel β-arrestin-biased AT1R ligands may yield promising drugs to combat AA. [ABSTRACT FROM AUTHOR]
Copyright of Hypertension (0194911X) is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0194911X
DOI:10.1161/HYPERTENSIONAHA.122.19232